Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Pain. 2015 Oct;156(10):1852–1863. doi: 10.1097/j.pain.0000000000000204

Figure 2. Spinally administered neuropeptide receptor antagonists reduced allodynia and unweighting at 4 weeks post-fracture.

Figure 2

Fracture (FX) rats were intrathecally injected with 20μg of the SP NK1 receptor antagonist LY303870 or 20μg of the CGRP CRLR receptor antagonist CGRP8-37. Both LY303870 and CGRP8-37 reduced hind paw mechanical allodynia (A) and unweighting (B) at 30 min after injection,compared to FX + Vehicle. Values are means ± SE. One-way ANOVA (p < 0.001) with Bonferroni post hoc testing ** P< 0.01 and *** P< 0.001 for FX + Vehicle (n=8), FX + LY303870 (n=8), or FX + CGRP8-37(n=8) vs Control (n=8), ### p< 0.001 for FX + LY303870 (n=8), or FX + CGRP8-37 (n=8) vs FX + Vehicle (n=8).